Drug Profile
Research programme: eye disorder therapeutics - Fovea/Institut de la Vision
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Fovea Pharmaceuticals; Institut de la Vision
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Eye-disorders in France
- 23 Mar 2011 Early research in Eye disorders in France (unspecified route)